Mechanisms of Heteroresistance and Resistance to Imipenem in Pseudomonas aeruginosa

References

• Oikonomou O, Panopoulou M, Ikonomidis A. Investigation of carbapenem heteroresistance among different sequence types of Pseudomonas aeruginosa clinical isolates reveals further diversity. J Med Microbiol. 2011;60:1556–1558. doi:10.1099/jmm.0.032276-021596913
   PubMed Web of Science ®Google Scholar
• Quale J, Bratu S, Gupta J, et al. Interplay of efflux system, ampC, and oprD expression in carbapenem resistance of Pseudomonas aeruginosa clinical isolates. Antimicrob Agents Chemother. 2006;50:1633–1641. doi:10.1128/aac.50.5.1633-1641.200616641429
   PubMed Web of Science ®Google Scholar
• El-Domany RA, Emara M, El-Magd MA, et al. Emergence of imipenem-resistant Pseudomonas aeruginosa clinical isolates from egypt coharboring VIM and IMP carbapenemases. Microbial Drug Resist. 2017;23:682–686. doi:10.1089/mdr.2016.0234
   Web of Science ®Google Scholar
• Alexander HE. Mode of action of streptomycin on type B Hemophilus influenzae. Am J Dis Child. 1948;75:428–430.18882067
   PubMedGoogle Scholar
• Nicoloff H, Hjort K, Levin BR, et al. The high prevalence of antibiotic heteroresistance in pathogenic bacteria is mainly caused by gene amplification. Nat Microbiol. 2019;4:504–514. doi:10.1038/s41564-018-0342-030742072
   PubMed Web of Science ®Google Scholar
• Band VI, Weiss DS. Heteroresistance: a cause of unexplained antibiotic treatment failure? PLoS Pathog. 2019;15:e1007726. doi:10.1371/journal.ppat.100772631170271
   PubMed Web of Science ®Google Scholar
• El-Halfawy OM, Valvano MA. Antimicrobial heteroresistance: an emerging field in need of clarity. Clin Microbiol Rev. 2015;28:191–207. doi:10.1128/cmr.00058-1425567227
   PubMed Web of Science ®Google Scholar
• Fernandez Cuenca F, Sanchez Mdel C, Caballero-Moyano FJ, et al. Prevalence and analysis of microbiological factors associated with phenotypic heterogeneous resistance to carbapenems in Acinetobacter baumannii. Int J Antimicrob Agents. 2012;39:472–477. doi:10.1016/j.ijantimicag.2012.01.01522445494
   PubMed Web of Science ®Google Scholar
• da Silva AEB, Martins AF, Nodari CS, et al. Carbapenem-heteroresistance among isolates of the Enterobacter cloacae complex: is it a real concern? Eur J Clin Microbiol Infect Dis. 2018;37:185–186. doi:10.1007/s10096-017-3138-x29170902
   PubMed Web of Science ®Google Scholar
• Tato M, Morosini M, Garcia L, et al. Carbapenem heteroresistance in VIM-1-producing Klebsiella pneumoniae isolates belonging to the same clone: consequences for routine susceptibility testing. J Clin Microbiol. 2010;48:4089–4093. doi:10.1128/jcm.01130-1020844213
   PubMed Web of Science ®Google Scholar
• Sun JD, Huang SF, Yang SS, et al. Impact of carbapenem heteroresistance among clinical isolates of invasive Escherichia coli in Chongqing, southwestern China. Clin Microbiol Infect. 2015;21:469.e1-10. doi:10.1016/j.cmi.2014.12.013
   Web of Science ®Google Scholar
• Mei S, Gao Y, Zhu C, et al. Research of the heteroresistance of Pseudomonas aeruginosa to imipenem. Int J Clin Exp Med. 2015;8:6129–6132.26131216
   PubMed Web of Science ®Google Scholar
• Band VI, Crispell EK, Napier BA, et al. Antibiotic failure mediated by a resistant subpopulation in Enterobacter cloacae. Nat Microbiol. 2016;1:16053. doi:10.1038/nmicrobiol.2016.5327572838
   PubMed Web of Science ®Google Scholar
• Lee HY, Chen CL, Wang SB, et al. Imipenem heteroresistance induced by imipenem in multidrug-resistant Acinetobacter baumannii: mechanism and clinical implications. Int J Antimicrob Agents. 2011;37:302–308. doi:10.1016/j.ijantimicag.2010.12.01521353490
   PubMed Web of Science ®Google Scholar
• Lister PD, Wolter DJ, Hanson ND. Antibacterial-resistant Pseudomonas aeruginosa: clinical impact and complex regulation of chromosomally encoded resistance mechanisms. Clin Microbiol Rev. 2009;22:582–610. doi:10.1128/cmr.00040-0919822890
   PubMed Web of Science ®Google Scholar
• Kohler T, Michea-Hamzehpour M, Epp SF, et al. Carbapenem activities against Pseudomonas aeruginosa: respective contributions of OprD and efflux systems. Antimicrob Agents Chemother. 1999;43:424–427. doi:10.1128/AAC.43.2.4249925552
   PubMed Web of Science ®Google Scholar
• He J, Jia X, Yang S, et al. Heteroresistance to carbapenems in invasive Pseudomonas aeruginosa infections. Int J Antimicrob Agents. 2018;51:413–421. doi:10.1016/j.ijantimicag.2017.10.01429127047
   PubMed Web of Science ®Google Scholar
• Ikonomidis A, Tsakris A, Kantzanou M, et al. Efflux system overexpression and decreased OprD contribute to the carbapenem heterogeneity in Pseudomonas aeruginosa. FEMS Microbiol Lett. 2008;279:36–39. doi:10.1111/j.1574-6968.2007.00997.x18070070
   PubMed Web of Science ®Google Scholar
• CLSI. Performance Standards for Antimicrobial Susceptibility Testing. 29th CLSI supplement M100 Wayne, PA: Clinical and Laboratory Standards Institute; 2019
   Google Scholar
• Tenover FC, Arbeit RD, Goering RV, et al. Interpreting chromosomal DNA restriction patterns produced by pulsed-field gel electrophoresis: criteria for bacterial strain typing. J Clin Microbiol. 1995;33:2233–2239. doi:10.1128/JCM.33.9.2233-2239.19957494007
   PubMed Web of Science ®Google Scholar
• Yin S, Chen P, You B, et al. Molecular typing and carbapenem resistance mechanisms of Pseudomonas aeruginosa Isolated from a Chinese burn center from 2011 to 2016. Front Microbiol. 2018;9:1135. doi:10.3389/fmicb.2018.0113529896186
   PubMed Web of Science ®Google Scholar
• Singh M, Yau YCW, Wang S, et al. MexXY efflux pump overexpression and aminoglycoside resistance in cystic fibrosis isolates of Pseudomonas aeruginosa from chronic infections. Can J Microbiol. 2017;63:929–938. doi:10.1139/cjm-2017-038028922614
   PubMed Web of Science ®Google Scholar
• Tomas M, Doumith M, Warner M, et al. Efflux pumps, OprD porin, AmpC beta-lactamase, and multiresistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients. Antimicrob Agents Chemother. 2010;54:2219–2224. doi:10.1128/aac.00816-0920194693
   PubMed Web of Science ®Google Scholar
• Rossi Goncalves I, Dantas RCC, Ferreira ML, et al. Carbapenem-resistant Pseudomonas aeruginosa: association with virulence genes and biofilm formation. Braz J Microbiol. 2017;48:211–217. doi:10.1016/j.bjm.2016.11.00428034598
   PubMed Web of Science ®Google Scholar
• Nielsen EI, Friberg LE. Pharmacokinetic-pharmacodynamic modeling of antibacterial drugs. Pharmacol Rev. 2013;65:1053–1090. doi:10.1124/pr.111.00576923803529
   PubMed Web of Science ®Google Scholar
• Andersson DI, Nicoloff H, Hjort K. Mechanisms and clinical relevance of bacterial heteroresistance. Nat Rev Microbiol. 2019;17:479–496. doi:10.1038/s41579-019-0218-131235888
   PubMed Web of Science ®Google Scholar
• Lin J, Xu C, Fang R, et al. Resistance and heteroresistance to colistin in Pseudomonas aeruginosa isolates from Wenzhou, China. Antimicrob Agents Chemother. 2019;63. doi:10.1128/aac.00556-19
   Web of Science ®Google Scholar
• Superti SV, Martins Dde S, Caierao J, et al. Indications of carbapenem resistance evolution through heteroresistance as an intermediate stage in Acinetobacter baumannii after carbapenem administration. Rev Inst Med Trop Sao Paulo. 2009;51:111–113. doi:10.1590/s0036-4665200900020001019390741
   PubMed Web of Science ®Google Scholar
• Rodriguez-Martinez JM, Poirel L, Nordmann P. Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2009;53:4783–4788. doi:10.1128/aac.00574-0919738025
   PubMed Web of Science ®Google Scholar
• Shu JC, Kuo AJ, Su LH, et al. Development of carbapenem resistance in Pseudomonas aeruginosa is associated with OprD polymorphisms, particularly the amino acid substitution at codon 170. J Antimicrob Chemother. 2017;72:2489–2495. doi:10.1093/jac/dkx15828535274
   PubMed Web of Science ®Google Scholar
• Fang ZL, Zhang LY, Huang YM, et al. OprD mutations and inactivation in imipenem-resistant Pseudomonas aeruginosa isolates from China. Infect Genet Evol. 2014;21:124–128. doi:10.1016/j.meegid.2013.10.02724211415
   PubMed Web of Science ®Google Scholar
• Kim CH, Kang HY, Kim BR, et al. Mutational inactivation of OprD in carbapenem-resistant Pseudomonas aeruginosa isolates from Korean hospitals. J Microbiol. 2016;54:44–49. doi:10.1007/s12275-016-5562-526727901
   PubMed Web of Science ®Google Scholar
• Yoon EJ, Kim D, Lee H, et al. Mortality dynamics of Pseudomonas aeruginosa bloodstream infections and the influence of defective OprD on mortality: prospective observational study. J Antimicrob Chemother. 2019;74:2774–2783. doi:10.1093/jac/dkz24531236593
   PubMed Web of Science ®Google Scholar
• Shu JC, Su LH, Chiu CH, et al. Reduced production of OprM may promote oprD mutations and lead to imipenem resistance in Pseudomonas aeruginosa carrying an oprD-group 1A allele. Microbial Drug Resist. 2015;21:149–157. doi:10.1089/mdr.2014.0116
   Web of Science ®Google Scholar
• Huang H, Jeanteur D, Pattus F, et al. Membrane topology and site-specific mutagenesis of Pseudomonas aeruginosa porin OprD. Mol Microbiol. 1995;16:931–941. doi:10.1111/j.1365-2958.1995.tb02319.x7476190
   PubMed Web of Science ®Google Scholar
• Li H, Luo YF, Williams BJ, et al. Structure and function of OprD protein in Pseudomonas aeruginosa: from antibiotic resistance to novel therapies. Int J Med Microbiol. 2012;302:63–68. doi:10.1016/j.ijmm.2011.10.00122226846
   PubMed Web of Science ®Google Scholar
• Rojo-Bezares B, Estepa V, Cebollada R, et al. Carbapenem-resistant Pseudomonas aeruginosa strains from a Spanish hospital: characterization of metallo-beta-lactamases, porin OprD and integrons. Int J Med Microbiol. 2014;304:405–414. doi:10.1016/j.ijmm.2014.01.00124594145
   PubMed Web of Science ®Google Scholar
• Kohler T, Michea-Hamzehpour M, Henze U, et al. Characterization of MexE-MexF-OprN, a positively regulated multidrug efflux system of Pseudomonas aeruginosa. Mol Microbiol. 1997;23:345–354. doi:10.1046/j.1365-2958.1997.2281594.x9044268
   PubMed Web of Science ®Google Scholar